WASHINGTON, July 14, 2025 /PRNewswire/ — Montage Marketing Group, a certified woman–owned small business based in the National Capital Region, is pleased to announce the official launch of its expanded Language Services capability. Rooted in strategy, research, and community engagement, these services provide clients with culturally authentic translations, localization, transcreation, and multilingual outreach—ready to elevate government, nonprofit, and enterprise communications.
Why Language Matters Now
In today’s interconnected world, reaching audiences isn’t just about translation—it’s about resonance. Montage combines data and analytics with linguistic expertise to craft messages that resonate across cultures, boosting engagement, trust, and equity.
Unique Capabilities: What Sets Montage Apart
Proven Case Studies
What This Means for Clients
Organizations now have access to a one–stop solution for inclusive, multilingual communications:
Contact & Next Steps
To learn how Montage can help your organization unlock deeper connections through strategic language services, please visit montagemarketinggroup.com/language. For inquiries or project proposals, contact:
Rodolfo Gil, Language Services Manager, Montage Marketing Group, rgil@montagemarketinggroup.com
About Montage Marketing Group
Montage is a passionate, creative team committed to “connections that make a difference,” offering everything from experience design and events to communications and outreach. As an 8(a) certified, woman–owned firm delivering services on the GSA MAS schedule, Montage blends marketing strategy, design, and data to serve government agencies, nonprofits, and private sector clients.
SOURCE Montage Marketing Group
New multilingual capabilities expand access to real-time GLP-1 dining guidance as WHO highlights the importance…
ATLANTA, GA AND DOHA, QATAR / ACCESS Newswire / December 6, 2025 / Ameerex Corporation…
SEATTLE, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage…
– Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial…
SPRING, Texas, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Io Therapeutics, Inc., a privately held pharmaceutical…
Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates consistent overall response rate and safety…